Live Breaking News & Updates on New England Retina Consultants

Stay updated with breaking news from New england retina consultants. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Keeping A Watchful Eye: Safety Reports in Geographic Atrophy Landscape

A headline year for retina disease drug development concurrently brought about research and discussion into the safety outcomes of these new agents. ....

United States , San Francisco , Iapocec Apellis , David Lally , Kunzmannk Apellis , Dilsher Dhoot , Veeral Sheth , Iapocec Charles Wykoff , Charles Wykoff , Nathan Steinle , Avacincaptad Pegol , Iapocec Pegcetacoplan , Iapocec Nathan Steinle , University Retina , Apellis Pharmaceuticals , Macula Associates , Drug Administration , American Society Of Retina Specialists , Apellis Pharmaceuticals Inc , American Academy Of Ophthalmology , Retina Consultants , New England Retina Consultants , American Society , Retina Specialists , Annual Meeting , California Retina Consultants ,

David Lally, MD: Perspective on ANX007 for Geographic Atrophy

At AAO 2023, David Lally, MD describes results from the phase 2 ARCHER study and the potential benefit of intravitreal ANX007 for patients with GA. ....

United States , San Francisco , David Lally , American Academy Of Ophthalmology , Annual American Academy , Retina Research Institute , New England Retina Consultants ,

Neuroprotective Agent Prevents Significant Vision Loss in Geographic Atrophy

Consistent vision effect with complement C1q inhibitor, despite no effect on lesion size ....

United States , Charles Bankhead , Los Angeles , David Lally , Mark Humayun , Subers Huang , Retina Center , American Academy Of Ophthalmology , University Of Southern California , New England Retina Consultants , American Academy , Southern California , Medpage Today , Retinal Late Breaking ,

ANX007 is a Potential Treatment for Geographic Atrophy, According to ARCHER Study

ARCHER study demonstrated that the antibody ANX007 was time and dose dependent, robust, and not dependent on lesion growth. ....

United States , San Francisco , David Lally , American Academy Of Ophthalmology , New England , New England Retina Consultants , Geographic Atrophy Secondary , Age Related Macular Degeneration , Selective Classical Complement Inhibitor , Annual American Academy ,

David Lally, MD: Efficacy of Oral APX3330 for Diabetic Retinopathy

Presented at ASRS 2023, results from the phase 2 ZETA-1 trial showed oral APX3330 missed its primary endpoint, but the consideration of a binocular treatment effect may warrant further clinical development. ....

United States , David Lally , American Society Of Retina Specialists , American Society , Retina Specialists , Annual Meeting , Retina Research Institute , New England Retina Consultants ,